APO Research
Talk to an analyst

APO RESEARCH · REPORT

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchPorcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market include Boehringer Ingelheim, Ceva, Merck, Pharmgate, Zoetis, SPAH, Huizhong Biological, Jiangsu Nannong Hi-Tech and Jinyu Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Company

Boehringer Ingelheim

Ceva

Merck

Pharmgate

Zoetis

SPAH

Huizhong Biological

Jiangsu Nannong Hi-Tech

Jinyu Biotechnology

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Type

One-dose Type

Two-dose Type

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Application

Piglet

Adult Pig

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine industry.

Chapter 3: Detailed analysis of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Trends Table 2. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Drivers Table 3. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Opportunities and Challenges Table 4. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Restraints Table 5. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue Share by Company (2021-2026) Table 7. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company, Product Type & Application Table 13. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of One-dose Type Table 18. Significant Companies of Two-dose Type Table 19. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Piglet Table 30. Significant Companies of Adult Pig Table 31. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Boehringer Ingelheim Company Information Table 64. Boehringer Ingelheim Business Overview Table 65. Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 67. Boehringer Ingelheim Recent Development Table 68. Ceva Company Information Table 69. Ceva Business Overview Table 70. Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 72. Ceva Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 77. Merck Recent Development Table 78. Pharmgate Company Information Table 79. Pharmgate Business Overview Table 80. Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 82. Pharmgate Recent Development Table 83. Zoetis Company Information Table 84. Zoetis Business Overview Table 85. Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 87. Zoetis Recent Development Table 88. SPAH Company Information Table 89. SPAH Business Overview Table 90. SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 92. SPAH Recent Development Table 93. Huizhong Biological Company Information Table 94. Huizhong Biological Business Overview Table 95. Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 97. Huizhong Biological Recent Development Table 98. Jiangsu Nannong Hi-Tech Company Information Table 99. Jiangsu Nannong Hi-Tech Business Overview Table 100. Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 102. Jiangsu Nannong Hi-Tech Recent Development Table 103. Jinyu Biotechnology Company Information Table 104. Jinyu Biotechnology Business Overview Table 105. Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio Table 107. Jinyu Biotechnology Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Distributors List Table 111. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Image Figure 2. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. One-dose Type Image Figure 10. Two-dose Type Image Figure 11. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type (2021-2032) Figure 17. Piglet Image Figure 18. Adult Pig Image Figure 19. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • One-dose Type
  • Two-dose Type
Applications
  • Piglet
  • Adult Pig
Companies covered
  • Boehringer Ingelheim
  • Ceva
  • Merck
  • Pharmgate
  • Zoetis
  • SPAH
  • Huizhong Biological
  • Jiangsu Nannong Hi-Tech
  • Jinyu Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Dynamics
  1. 2.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Trends
  2. 2.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Drivers
  3. 2.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Opportunities and Challenges
  4. 2.4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Industry Restraints
3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Company
  1. 3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Product Type and Application
  8. 3.8 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Type
  1. 4.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Type Introduction
  2. 4.1.1 One-dose Type
  3. 4.1.2 Two-dose Type
  4. 4.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type
  5. 4.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type
  9. 4.3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type (2021-2032)
5 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Application
  1. 5.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Application Introduction
  2. 5.1.1 Piglet
  3. 5.1.2 Adult Pig
  4. 5.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application
  5. 5.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application
  9. 5.3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application (2021-2032)
6 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Country, 2025 VS 2032
7 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Ceva
  8. 8.2.1 Ceva Company Information
  9. 8.2.2 Ceva Business Overview
  10. 8.2.3 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ceva Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  12. 8.2.5 Ceva Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Pharmgate
  20. 8.4.1 Pharmgate Company Information
  21. 8.4.2 Pharmgate Business Overview
  22. 8.4.3 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pharmgate Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  24. 8.4.5 Pharmgate Recent Developments
  25. 8.5 Zoetis
  26. 8.5.1 Zoetis Company Information
  27. 8.5.2 Zoetis Business Overview
  28. 8.5.3 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Zoetis Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  30. 8.5.5 Zoetis Recent Developments
  31. 8.6 SPAH
  32. 8.6.1 SPAH Company Information
  33. 8.6.2 SPAH Business Overview
  34. 8.6.3 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SPAH Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  36. 8.6.5 SPAH Recent Developments
  37. 8.7 Huizhong Biological
  38. 8.7.1 Huizhong Biological Company Information
  39. 8.7.2 Huizhong Biological Business Overview
  40. 8.7.3 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Huizhong Biological Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  42. 8.7.5 Huizhong Biological Recent Developments
  43. 8.8 Jiangsu Nannong Hi-Tech
  44. 8.8.1 Jiangsu Nannong Hi-Tech Company Information
  45. 8.8.2 Jiangsu Nannong Hi-Tech Business Overview
  46. 8.8.3 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Nannong Hi-Tech Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  48. 8.8.5 Jiangsu Nannong Hi-Tech Recent Developments
  49. 8.9 Jinyu Biotechnology
  50. 8.9.1 Jinyu Biotechnology Company Information
  51. 8.9.2 Jinyu Biotechnology Business Overview
  52. 8.9.3 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jinyu Biotechnology Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Product Portfolio
  54. 8.9.5 Jinyu Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Value Chain Analysis
  2. 9.1.1 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Mode & Process
  6. 9.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Distributors
  9. 9.2.3 Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst